Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 237 of the 237 references it cites were found in a registry or an index; 90 of the 249 sources its claims cite were checked for support.

The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer

Open access

Abstract

Advances in antibody-drug conjugate (ADC) technology and identification of new antigen targets are repositioning ADCs as a promising therapeutic platform for metastatic castration-resistant prostate cancer (mCRPC). This review summarizes recent progress in ADC payload and linker chemistry, highlights membrane antigens in prostate cancer that have demonstrated encouraging antitumor activity in clinical trials, and addresses strategies to mitigate off-target toxicity. These advances position ADCs to transform the therapeutic landscape of mCRPC.

Overview

CoChat Summary

## TL;DR

This is a narrative review of antibody-drug conjugates (ADCs) for prostate cancer, focused on payloads, linker chemistry, and molecular targets most relevant to metastatic castration-resistant prostate cancer (mCRPC). It concludes that ADCs remain promising but none are yet approved for prostate cancer because safety, target heterogeneity, and payload delivery remain major barriers.

## Key findings

  • The review states that ADC development in prostate cancer is being driven by advances in payload and linker chemistry and by targets such as PSMA, B7H3, STEAP1, TROP2, and CD46.
  • Several early trials showed signal of activity:
  • FOR46 in mCRPC: 14/31 (45%) evaluable patients had PSA50 responses, and 8/18 (44%) had tumor regression.
  • ARX517 in 24 mCRPC patients: ≥50% PSA and ctDNA decline were observed at 2.8 mg/kg, with RECIST responses in 2/7 patients with measurable soft tissue disease.
  • Ifinatamab deruxtecan (B7H3-DXd): among 59 evaluable heavily pretreated mCRPC patients, 15 had partial or complete responses, with average DOR 6.4 months and PFS 4.8 months.
  • Some ADC programs were stopped because of toxicity or limited benefit:
  • MLN2704 had 71% dose-limiting peripheral neuropathy and was discontinued.
  • PSMA ADC had 24% grade ≥3 neurotoxicity, 8% neutropenia, and 3 sepsis-related deaths.
  • ASG-5ME caused substantial toxicity, including 2 treatment-related deaths, and was discontinued.
  • The review highlights that 177Lu-PSMA-617 improved median overall survival and radiographic PFS versus best standard of care in VISION and is FDA-approved, underscoring the importance of PSMA as a validated prostate cancer target.

## Methods

  • Narrative review of ADCs for prostate cancer, synthesizing preclinical and clinical evidence on payloads, linker technologies, and molecular targets.
  • Uses published clinical trial results and identifies completed and ongoing studies in prostate cancer, especially mCRPC.
  • Main analysis is qualitative comparison of target biology, ADC design features, efficacy signals, and toxicity patterns across agents.

## Limitations

  • The paper explicitly notes that no ADCs have yet been approved for prostate cancer because of safety and specificity issues.
  • It states that mCRPC presents intrinsic challenges for ADCs: dense stroma, low vascularity, and high intertumor heterogeneity limit penetration and distribution.
  • Evident from the text: much of the prostate cancer evidence is early-phase, often with small cohorts, and several agents have no prostate-cancer-specific published data yet, limiting definitive conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41698-025-01131-0

Cites

237 of 237 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Mechanism of action, target antigens, and cytotoxic payloads of ADCs in prostate cancer. A Mechanism of action of ADC involves antibody-antigen binding, endocytosis, endo-lysosomal fusion, lysosomal degradation, and release of the cytotoxic payload. B Potential antigen targets in prostate tumors include PSMA, STEAP1, B7H3, TROP2, CD46, Tissue Factor, DLL3, SLC44A4, HER2, HER3, Nectin-4, 5T4, KAAG1, ASCT-2, LYPD3, Tag-72, TMS4F1, CDH3, ROR1, and PSCA. C ADCs currently employ three classes of cytotoxic payloads. Microtubule-disrupting agents (maytansinoids, tubulysin, and auristatin) inhibit tubulin polymerization. Camptothecin derivatives (irinotecan, topotecan, exatecan mesylate, deruxtecan) inhibit topoisomerase I (TOPI). DNA alkylating agents (pyrrolobenzodiazepine and duocarmycin) cause DNA crosslinks, ultimately leading to apoptosis.
Fig. 1 Mechanism of action, target antigens, and cytotoxic payloads of ADCs in prostate cancer. A Mechanism of action of ADC involves antibody-antigen binding, endocytosis, endo-lysosomal fusion, lysosomal degradation, and release of the cytotoxic payload. B Potential antigen targets in prostate tumors include PSMA, STEAP1, B7H3, TROP2, CD46, Tissue Factor, DLL3, SLC44A4, HER2, HER3, Nectin-4, 5T4, KAAG1, ASCT-2, LYPD3, Tag-72, TMS4F1, CDH3, ROR1, and PSCA. C ADCs currently employ three classes of cytotoxic payloads. Microtubule-disrupting agents (maytansinoids, tubulysin, and auristatin) inhibit tubulin polymerization. Camptothecin derivatives (irinotecan, topotecan, exatecan mesylate, deruxtecan) inhibit topoisomerase I (TOPI). DNA alkylating agents (pyrrolobenzodiazepine and duocarmycin) cause DNA crosslinks, ultimately leading to apoptosis.CC BY-NC-ND · PubMed Central
Fig. 2 Future advancements in ADC development to improve safe and sufficient payload delivery and increase antitumor efficacy. Improvements in linker, antibody, and payload technology, the utilization of precision medicine to identify markers of sensitivity and resistance in tumors, and combination therapy with radioligands all represent avenues for the future of ADCs.
Fig. 2 Future advancements in ADC development to improve safe and sufficient payload delivery and increase antitumor efficacy. Improvements in linker, antibody, and payload technology, the utilization of precision medicine to identify markers of sensitivity and resistance in tumors, and combination therapy with radioligands all represent avenues for the future of ADCs.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

69 Valid · 8 Not valid · 103 Not checked · 9 Own results and interpretations

69 more claims · 23 with their cited sources checked

Create a free account to see all 189 claims and to verify the 40 references still open.

See all claims — free account
  • It may state two separate claims as one. 111
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 228 references

Research works printed but not linked: 1

  1. Klaassen, Z. ASCO 2025: DB‑1311/BNT324 (A Novel B7H3 ADC) in Patients with Heavily Pretreated CRPC, https://www.urotoday.com/conference-highlights/asco-2025/asco-2025-prostate-cancer/160832-asco-2025-db-1311-bnt324-a-novel-b7h3-adc-in-patients-with-heavily-pretreated-crpc.html (2025).

Cited by

See all 20

Metadata

Authors
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A.
Affiliations
  • Brown University (US)
  • University of California, San Francisco (US)
Corresponding author
Carneiro, Benedito A.
Venue
npj Precision Oncology
Published
2025-11-14
Volume
9
Issue
1
Pages
351-351
ISSN
2397-768X (ISSN-L)
OpenAlex
W4416225775
Cited by
20
References
228
Citations by year
2026: 20
FWCI
3.46
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Precision Oncology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Pfizer
  • AstraZeneca
  • Daiichi Sankyo Europe
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
antibody-drug conjugates, prostate cancer, metastatic castration-resistant prostate cancer, linker chemistry, membrane antigens, off-target toxicity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. https://app.cochat.ai/papers/10.1038/s41698-025-01131-0
The paper
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025). The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. npj Precision Oncology. https://doi.org/10.1038/s41698-025-01131-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.